BioStem Technologies Set to Reveal Q3 2025 Results Soon

Author: Dylan Bailey Updated: 10-30-2025 04:19 PM

Upcoming Financial Results Announcement

BioStem Technologies, Inc. (OTC: BSEM) is gearing up to unveil its financial results for the third quarter of 2025 on an exciting date of November 13. All eyes will be on the company's conference call and webcast scheduled for 4:30 PM ET, where key insights about the quarter will be shared.

What to Expect from the Conference Call

The event will showcase a detailed overview presented by Jason Matuszewski, the company's CEO, and Brandon Poe, the CFO. They will delve into the highlights and key performances during the quarter, giving investors and stakeholders a clearer picture of BioStem's achievements and milestones reached within this period.

How to Access the Webcast

Participation is straightforward; interested parties can join through the conference call by utilizing the provided details. Those looking to catch the live insights will benefit from registering in advance, ensuring they do not miss this informative session.

Conference Call & Webcast Details

Conference ID: 9695874
Toll-Free Access (North America): (800) 715-9871
International Dial-In: +1 (646) 307-1963
Webcast Link: Live Webcast

About BioStem Technologies, Inc.

BioStem Technologies is a pioneer in the MedTech sector, dedicated to the creation, manufacturing, and marketing of innovative placental-derived products aimed at advancing wound care. Their proprietary BioREtain processing method allows the company to produce allografts that maintain the natural properties of perinatal tissues, effectively contributing to regenerative therapies. BioStem’s commitment to quality is reflected in its adherence to rigorous standards and certifications, including those from the American Association of Tissue Banks.

Products and Innovations

The company’s portfolio comprises several high-quality brands, such as AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each product is meticulously processed at BioStem’s FDA-registered and AATB-accredited facility located in Pompano Beach, ensuring that they meet the highest industry standards. BioStem's focus on research and development in regenerative medicine enhances their ability to impact lives positively, solidifying their reputation in the healthcare community.

Staying Connected with BioStem

BioStem encourages interested individuals to stay updated with their latest developments by subscribing to their distribution list. This is an excellent way to receive news about product launches, advancements in technology, and financial disclosures straight to your inbox.

Contact Information

For inquiries, you can visit www.biostemtechnologies.com. For direct contact, reach out via email at info@biostemtech.com or call at 954-380-8342.

Frequently Asked Questions

What is the date for BioStem's Q3 2025 results?

The financial results will be announced on November 13, 2025.

Who will present during the conference call?

Jason Matuszewski, the CEO, and Brandon Poe, the CFO, will present the results and insights during the call.

How can one access the conference call?

Access details, including toll-free numbers and a webcast link, will be provided ahead of the event.

What types of products does BioStem Technologies offer?

BioStem specializes in placental-derived products, focusing on advanced wound care through innovative allografts.

How can I stay updated with BioStem Technologies?

Those interested can join BioStem's distribution list or follow them on social media platforms to receive the latest news and updates.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.